A Randomized, Double blind, Placebo controlled, Multi-centric, Interventional, Prospective Clinical study to Evaluate Efficacy and Safety of Ayumem Capsule in subjects with Stress and Insomnia. - NI

Welex Laboratories Pvt Ltd0 sites61 target enrollmentStarted: TBDLast updated: November 24, 2021

Trial Snapshot

No summary available.

•1.Subjects who perceive themselves to be under stress and having a score of between 14 -24 on the Perceived Stress Scale (PSS).
•2.Subjects not having any other psychiatric conditions than stress.
•3.Subjects willing to follow the procedures as per the study protocol and voluntarily sign an informed consent form

•1.Subjects suffering from any chronic physical, hormonal or psychiatric illness.
•2.Subjects using oral or systemic contraceptive medications.
•3.Subjects with uncontrolled diabetes and hypertension.
•4.Subjects with substance dependence.
•5.Chronic alcoholics and Habitual Tobacco chewers.
•6.Known cases of Severe/Chronic hepatic or renal disease.
•7.Known subject of any active malignancy.
•8.Subjects giving history of significant cardiovascular event <12 weeks prior to recruitment.
•9.Subjects having known chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.
•10.Known subjects of having active metabolic or gastrointestinal diseases that may interfere with nutrient absorption, metabolism, or excretion, excluding diabetes.
•11.Subjects using any other investigational drug within 1 month prior to recruitment or Subjects currently participating in any other Clinical study.
•12.Known hypersensitivity to any of the ingredients used in study drug.
•13.Pregnant and Lactating females.
•14.Any other condition due to which patients are deemed to be unsuitable by the investigator for reason(s) not specifically started in the exclusion criteria.

Sponsor

Welex Laboratories Pvt Ltd